<DOC>
	<DOC>NCT01947998</DOC>
	<brief_summary>This prospective cohort study will provide information about: characteristics of Rivaroxaban use in patients who are prescribed Rivaroxaban for the first time compared to patients who are prescribed Warfarin for the first time, the occurrence of intracranial haemorrhage, gastrointestinal and urogenital bleeding, and the occurrence of non-infective liver disease.</brief_summary>
	<brief_title>Study of Rivaroxaban Use and Potential Adverse Outcomes in Routine Clinical Pratice (UK)</brief_title>
	<detailed_description />
	<mesh_term>Embolism</mesh_term>
	<mesh_term>Pulmonary Embolism</mesh_term>
	<mesh_term>Rivaroxaban</mesh_term>
	<mesh_term>Warfarin</mesh_term>
	<criteria>Patients between 2 and 89 years, who have been prescribed for the first time either Rivaroxaban or Warfarin.</criteria>
	<gender>All</gender>
	<minimum_age>2 Years</minimum_age>
	<maximum_age>89 Years</maximum_age>
	<verification_date>March 2017</verification_date>
	<keyword>Rivaroxaban,</keyword>
	<keyword>Pulmonary Embolism,</keyword>
	<keyword>Venous Thrombosis,</keyword>
	<keyword>Venous Thromboembolism,</keyword>
	<keyword>Acute Coronary Syndrome,</keyword>
	<keyword>Intracranial Hemorrhages,</keyword>
	<keyword>Gastrointestinal Hemorrhage,</keyword>
	<keyword>Warfarin</keyword>
</DOC>